Organ-on-Chip & Organoids
MIMETAS OrganoPlate
by MIMETAS B.V.
High-throughput 3D tissue models on OrganoPlate enabling scalable organ-on-chip drug screening
Category
Organ-on-Chip & Organoids
Founded
2013
Headquarters
Leiden, Netherlands
Overview
MIMETAS develops the OrganoPlate platform, a microfluidic chip system formatted as a standard 384-well plate that enables simultaneous culture of up to 96 independent 3D tissue models with perfusion. Unlike traditional organ-on-chip devices that run one experiment per chip, OrganoPlate uses phaseguide technology to pattern 3D hydrogel channels adjacent to perfused cell culture lanes without the need for membranes or physical barriers. This allows tubular, perfused tissue structures — including gut, kidney, liver, and vascular tissues — to be formed and maintained in a standard lab workflow. Pharmaceutical and cosmetic companies use OrganoPlate for compound toxicity screening, drug absorption and transport studies (ADME), and disease modeling at a throughput compatible with early drug discovery. Key customers include AstraZeneca, Janssen, and multiple European pharma companies. The platform is compatible with standard liquid handling robots and plate readers, integrating readily into existing high-throughput screening infrastructure. MIMETAS's primary differentiator is its scalable throughput: the OrganoPlate format allows 40-96 tissue models per plate, enabling dose-response curves and multi-compound screens that single-channel chip platforms cannot match. The company's phaseguide technology — a passive, pressure-driven method for gel patterning — eliminates the need for complex external pumping systems during chip loading. MIMETAS was acquired by Gentronix in 2024 and continues expanding its assay portfolio, including gut permeability and renal proximal tubule transporter assays validated against clinical outcomes.
Key Features
Real-Time Tissue Sensing
Embedded sensors capture dynamic tissue responses including TEER, oxygen, and metabolite levels.
Standardized Culture Protocols
Reproducible protocols ensuring consistency across labs and experimental batches.
Disease Modeling
Recreate disease-specific tissue models including fibrosis, inflammation, and tumor microenvironments.
Imaging & Analysis
Integrated confocal imaging and AI-powered image analysis for organoid phenotyping.
Toxicity Prediction
Predict organ-specific drug toxicity using human tissue models as alternatives to animal testing.
Pros & Cons
Pros
- +High-throughput organoid screening platforms test thousands of compounds per experiment
- +Standardized culture protocols ensure reproducibility across labs and experimental batches
- +Real-time sensing and imaging capture dynamic tissue responses to drug exposure
- +Microfluidic organ chips recapitulate human tissue-level physiology for predictive drug testing
- +Multi-organ systems model drug absorption, distribution, metabolism, and excretion in vitro
- +Patient-derived organoids enable personalized drug screening for precision oncology applications
Cons
- −Specialized equipment and expertise required for organ chip operation limits broad adoption
- −Organoid variability between batches and labs creates reproducibility challenges
- −Current organ chips cannot fully recapitulate the complexity of whole-organ physiology
- −High per-unit costs for microfluidic chips limit throughput compared to traditional cell culture
- −Regulatory acceptance of organ-chip data as replacement for animal testing is still developing
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.